Boston Scientific lifts 2025 outlook following 29% Q2 cardiovascular profit rise
The company now anticipates an adjusted profit of $2.95 to $2.99 per share for 2025, raising its previous guidance of $2.87 to $2.94.
Boston Scientific's financials revealed total sales of more than $5bn in Q2 2025, representing a 22.8% rise on Q2 2024 at $4.12bn, with shares in the company rising by over 4% following the result's announcement.
The majority of the quarter's profits emanated from the US-based company's cardiovascular unit at $3.34bn – representing a 26.8% increase on the unit's Q2 2024 performance at $2.63bn.
GlobalData medical analyst David Beauchamp noted that since its emergence, PFA has displaced most other approaches to treating atrial fibrillation (AFib) such as radiofrequency (RF) and cryoablation. Meanwhile, Boston Scientific only has competition in the space from Medtronic and Johnson & Johnson (J&J).
Boston Scientific gained US Food and Drug Administration (FDA) approval on Farapulse in January 2024, a month after Medtronic's approval for its PulseSelect PFA system. J&J secured approval for its Varipulse PFA system in November 2024.
Beauchamp said: 'Boston Scientific also has had widespread success with their WATCHMAN series of left atrial appendage closure devices.
'It's not shocking to see them increasing their profit expectations, as they have been consistently successful for years and their device quality is very high.'
Elsewhere across the business, Boston Scientific reported a 26.9% rise to $676m in its urology unit, up from $525m in Q2 2024. The company's peripheral intervention division also saw a significant increase of 18.3% to $698m versus $590m in Q2 2024.
Boston Scientific's chairman and CEO Mike Mahoney commented: 'This was another excellent quarter – marked by exceptional top-line performance – that delivered margin expansion and prioritised investment for future growth.'
Reflecting on the quarter during an earnings call with analysts, the company's CFO John Monson said that sales for medical device makers such as Boston Scientific had been boosted due to a growth in surgical procedures, thereby helping ameliorate broader concerns about healthcare spending concerning the Trump administration's proposed tariffs.
However, Monson commented: "Based on the current schedule of expected tariffs, we now anticipate a full-year headwind of about $100m, down from a $200m estimate.'
According to GlobalData analysis, months after the approval of Farapulse and Medtronic's PulseSelect, physicians in the US had already started displaying a much stronger preference for Farapulse over PulseSelect.
J&J also released its Q2 2025 financials last week, reporting a 7.3% rise in its Medtech unit on Q2 2024 to around $8.54m. Since its FDA approval in 2024, J&J's Varipulse PFA system has clearly had an effect on the Medtech unit's performance, albeit to a lesser extent than Farapulse given that Boston Scientific's PFA system has had a slight head start in the market.
"Boston Scientific lifts 2025 outlook following 29% Q2 cardiovascular profit rise" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
6 minutes ago
- Forbes
Cancer Survivors: If You're A Hero, Why Are You Hiding It?
Love, bonding and woman with her mom with cancer hugging, sitting and spending time together. Happy, ... More sweet and sick mature female person embracing her adult daughter with a smile in outdoor garden. Cancer survivors have a great story to tell. They should tell it. I started this campaign 15 years ago – and here's the latest iteration. Over the last few weeks, I spoke with five interesting people who had five things in common. Here are the first four. They are all cancer survivors, they are all returning to the workplace after a long battle, they are all having a monumentally hard time getting a job, and they are all over 55. However, the fifth thing they have in common is why today's column came to be. They are all doing everything they can to hide these facts, especially the first one: the cancer. Now jump to thing five, the difficulty in finding a job. That's why I got their calls and emails. I gave them all the same advice. Tell people about it. Don't hide it. Get it out front and out of the way. This seemed counterintuitive to them – it may to you as well – and when I first laid it out, it made them uncomfortable. By the time we finished our conversations, though, they all agreed. And I'll bet many people reading this disagree initially, too. In fact, the advice these five people had gotten from everyone to whom they had previously spoken was opposite to mine – don't mention it, don't bring it up, don't discuss it, employers are not allowed to ask about that, if employers know they'll never hire you, it's none of their business, your previous employer is not allowed to mention it. And so on, ad infinitum. Well then, if that's the right advice, why are these people unable to find work? If they've hidden these facts, shouldn't that – based on those others' advice – lead to job opportunities? No, because it's bad advice. If you follow that line of strategic (?) thinking, and it goes month after month – in two cases, over a year – doesn't that indicate it might be faulty? This advice came from people who meant well: doctors, social workers, psychologists, religious leaders, people from the state department of labor, lawyers, family, friends, and so on. They just don't know the realities of the job market. In each case, we got around to how these five answered the 'what-have-you-been-doing-since-your-last-job?' and 'why-did-you-leave-your-last-job?' questions. OK, so how did they answer those questions? With every half-baked cockamamie answer you can think of, none of which holds water. Other than the truth, any answer is weak and suspect. If you think otherwise, go ahead; try any other answer and get back to me if you come up with one that sounds convincing – and that sounds like one that will move you to the second round of interviews. Now, one might think this is asking for trouble, that (as they all said) employers would not hire them due to fear they would get sick again and … you know the rest. Underneath it all, what's wrong with all this is that, in the eyes of many – me included – cancer survivors are heroes, and nothing less. They know all about the important things in life, like vision, determination, patience, goals, positive thinking, decision-making, responsibility, team work, bravery, and fortitude. Are these not the characteristics an employer looks for? So why hide this? Is it because you feel you'll get fewer calls or second interviews? Indeed you will, but that's OK. This deception game is the same faulty thinking that goes into the hide-my-age-by-leaving-stuff-off-my-resume fallacy. C'mon, some employers might be unfair to older workers or cancer survivors or anyone else, but they're not stupid. Whatever you try to hide will come out sooner or later. If you do the deceptive dance, they'll just find out later (not sooner), and then you'll just have wasted an awful lot of your time, not to mention keeping your hopes up artificially. So my suggestion is this. Start your cover letters off with a bold statement: 'After spending the last 10 months battling cancer, I have won that battle and am now re-entering the workplace.' Continue your letter as you would normally. You know what's going to happen? For sure, you will get fewer responses. But the ones you get are going to be real – very real. Don't you think there are people who admire what you've done? Don't you think a large number of hiring managers have either had the same experience you did or had a family member who did? Don't you think there are companies who are such avid supporters of cancer research that they sponsor 5K runs, Relay for Life, and other events in which we now all participate? The answers are yes, yes, and yes. And don't you think that, to these companies and managers, you're a hero? Yes again. Well then, let them know! The ones who will disqualify you because of what you've been through are jerks, and if by any slim chance you get this by them initially, what do you think will happen once this comes out? Jerks are always jerks; don't forget that. I'll take fewer calls any day of the week if they're sincere and real, wouldn't you? And if you can create the conditions under which that happens, why wouldn't you? Do not lose sight of one thing. You're a hero. And if you're a hero, why are you hiding it? P.S. I subsequently received letters of thanks from two different offices of the Aamerican Cancer Society, one of which published it in their newsletter. E.
Yahoo
28 minutes ago
- Yahoo
Zacks Industry Outlook Highlights Exxon Mobil, Chevron and Shell
For Immediate Release Chicago, IL – July 25, 2025 – Today, Zacks Equity Research discusses Exxon Mobil Corp. XOM, Chevron Corp. CVX and Shell plc SHEL. Industry: Integrated Energy Link: The crude oil pricing environment is expected to experience significant volatility this year, which will negatively impact the exploration and production activities of integrated energy companies. A deceleration in oil production growth can create challenges, thereby constraining earnings from upstream operations. At the same time, the accelerating shift toward renewable energy is introducing greater uncertainty to the Zacks Oil and Gas Integrated International industry's prospects. This combination of factors suggests a challenging and softened industry environment that is expected to persist through at least the remainder of 2025. Among the companies in the industry that will probably survive the business challenges are Exxon Mobil Corp., Chevron Corp. and Shell plc. About the Industry The Zacks Oil and Gas Integrated International industry covers companies primarily involved in upstream, midstream and downstream operations. These companies have upstream businesses in the United States (including prolific shale plays and the deepwater Gulf of Mexico), Asia, South America, Africa, Australia and Europe. Midstream operations of energy companies entail transporting oil, natural gas liquids and refined petroleum products. In downstream businesses, the firms buy raw crude to produce refined petroleum products. The companies' downstream activities involve chemical businesses that manufacture raw materials for making plastics. The integrated players are now gradually focusing on renewables, leading to the energy transition. The firms aim to lower emissions from operations and cut the carbon intensity of the products sold. 3 Trends Shaping the Future of the Industry The integrated energy sector is currently navigating a highly uncertain and challenging macroeconomic environment. Refining, renewable energy and chemical segments are particularly under pressure due to limited visibility into future market dynamics. Escalating trade tensions are compounding this uncertainty, raising concerns over potential economic slowdowns. Meanwhile, oil prices remain volatile, swayed by geopolitical risks and fluctuating OPEC+ production strategies. As a result, major integrated energy players are grappling with profitability challenges. There has been a slowdown in oil production growth in the upstream businesses of integrated energy companies in the United States due to shareholder demands for a greater focus on returning capital rather than investing in production expansion. As production growth slows, output decreases, which can lead to reduced revenues. Since upstream operations depend heavily on volume to generate income, any stagnation in production growth has a direct and negative impact on their bottom line. Governments, investors and stakeholders are placing growing emphasis on addressing climate change, leading to an increased demand for renewable energy. Consequently, the demand for products reliant on oil, natural gas and natural gas liquids is expected to decline, with solar and wind energy gaining prominence in the energy landscape. The integrated energy firms are adversely impacted by these trends as they are primarily engaged in the production and transportation of fossil fuels, such as oil, and the sale of refined petroleum products. Zacks Industry Rank Indicates Bearish Outlook The Zacks Oil and Gas Integrated International industry is part of the broader Zacks Oil - Energy sector. It carries a Zacks Industry Rank #189, which places it in the bottom 23% of the 245 Zacks industries. The group's Zacks Industry Rank, which is the average of the Zacks Rank of all the member stocks, indicates bleak near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Before we present a few stocks that you may want to consider, let us take a look at the industry's recent stock market performance and valuation picture. Industry Lags S&P 500 & Sector The Zacks Oil and Gas Integrated International industry has underperformed the broader Zacks Oil - Energy sector and the Zacks S&P 500 composite over the past year. The industry has plunged 5.4% over this period compared with the S&P 500's growth of 17.3% and the broader sector's decline of 2.6%. Industry's Current Valuation Since oil and gas companies are debt-laden, it makes sense to value them based on the Enterprise Value/Earnings before Interest Tax Depreciation and Amortization (EV/EBITDA) ratio. This is because the valuation metric takes not just equity into account but also the level of debt. On the basis of the trailing 12-month EV/EBITDA, the industry is currently trading at 4.27X, lower than the S&P 500's 17.85X. It is also below the sector's trailing 12-month EV/EBITDA of 4.77X. Over the past five years, the industry has traded as high as 6.54X and as low as 2.75X, with a median of 4.11X. 3 Integrated International Stocks to Watch Chevron: The company completed its $53-billion acquisition of Hess Corporation, thereby strengthening its upstream portfolio and obtaining a 30% interest in the highly valued Stabroek Block offshore Guyana. Chevron gains strategic access to one of the most prolific deepwater discoveries of the past decade, estimated to hold more than 11 billion barrels of recoverable oil. The acquisition also strengthens its position in the U.S. Bakken shale, the Gulf of Mexico and Southeast Asia. It currently carries a Zacks Rank #3 (Hold). The move comes as a turning point for Chevron as it is facing mounting pressure to replenish its reserves and strengthen free cash flow amid ongoing volatility in the oil markets. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. ExxonMobil: The company's acquisition of Pioneer Natural Resources expanded its production capabilities in the Permian Basin, one of the most profitable regions in the United States due to its inexpensive production costs. XOM boasts a strong portfolio of upstream assets, focused on oil-rich resources in the Permian Basin and offshore Guyana. Production costs in those assets are low. Therefore, the leading integrated energy major can overcome a collapse in oil and gas prices. Similar to its operations in the Permian, ExxonMobil boasts a robust project pipeline in offshore Guyana resources. It presently carries a Zacks Rank #3. Shell: The company's acquisition of Pavilion Energy strengthens its LNG trading capabilities and positions itself for long-term growth in cleaner fuels. Shell's position as a major supplier of LNG should help the company meet the fuel's growing demand and improve its cash flow. Shell, with a Zacks Rank of 3, is targeting a 4-5% annual increase in LNG sales over the next five years and 1% annual production growth. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Shell PLC Unsponsored ADR (SHEL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
34 minutes ago
- Yahoo
Marine veteran's brain returned by funeral home in an unmarked and leaking box, lawsuit claims
A couple is suing two funeral homes after their veteran son's brain was returned in an unmarked cardboard box that was leaking 'biohazardous liquid,' a lawsuit alleges. Lawrence and Abbey Butler are suing Nix & Nix Funeral Homes in Pennsylvania and Southern Cremations & Funeral in Georgia for the 'mishandling' of the remains of their son Timothy Garlington, a Marine veteran who died in November 2023. He died in Georgia, but was originally from Pennsylvania. In November, the couple hired Southern Cremations & Funerals to transport their son's remains to Nix & Nix Funeral Home in Philadelphia. A week later, Lawrence Butler picked up a 'white, unmarked cardboard box' that the couple thought contained their son's personal belongings, the filing states. The box began to smell and leak fluids in Butler's car. When the couple tried to remove the box, 'biohazardous liquid spilled' onto them, the lawsuit alleges. They reached out to the funeral homes to learn that the box contained their late son's brain. "The family has been destroyed twice," their lawyer, L. Chris Stewart, told Fox 5. The couple says they suffered 'serious mental and emotional distress' as a result of the funeral homes' mishandling of their son's remains, the suit stated. It called the defendants' conduct 'extreme and outrageous.' They've accused the defendants of negligence and intentional infliction of emotional distress, among other claims, for an unspecified amount in damages. 'It was, and it is still, in my heart that I got in my car and I smelled death,' Lawrence Butler told the Associated Press. 'I had to get rid of that car,' he added. 'I just couldn't stand the idea that the remains were in that car.' Stewart told the AP that after speaking to several other funeral homes, he learned the brain is not typically 'separated from [the] body in that fashion and shipped in that fashion.' In the circumstances that the body parts are separated, they are labeled as a biohazard. 'There's no excuse, there is zero excuse for this type of error to happen. For the Georgia funeral home, Southern Cremations, to ship unmarked, bio-hazardous material. For the funeral home here in Philadelphia to hand the parents an unmarked box, not examined, not on a list of the inventory that was the personal items, to not check it,' Stewart told the AP. 'They have not received a single apology to this day from any funeral home.' The owner of Nix & Nix Funeral Homes said that his team didn't know that the box contained brain matter and noted that the state board did a thorough investigation and cleared them of wrongdoing. "Any body parts should be in the body. I don't understand why they would send his brains in a box, a regular box," Julian Nix, the owner of Nix and Nix Funeral Home, told Fox 5. "We immediately reported it to the state board and the medical examiner for inspection," Nix told the outlet. "When the state board investigated, they said that we did everything correct."
